WJPMR, 2026, 12(6), 55-62

Review Article

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Impact Factor: 7.555

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

CADASIL AND CARASIL: A MUTATED HEREDITARY LEUKOENCEPHALOPATHY – NEW FINDINGS

***[1]Abinaya Arulappan, [2]Venkateswaramurthy Nallasamy**

*[1]Pharm D, JKKN College of Pharmacy, Komarapalayam, Namakkal, 638183, Tamil Nadu, India.
[2]Professor and Head, JKKN College of Pharmacy, Komarapalayam, Namakkal, 638183, Tamil Nadu, India.

***Corresponding Author: Abinaya Arulappan**

India.

DOI: https://doi.org/10.5281/zenodo.20444809

How to cite this Article: *1Abinaya Arulappan, Venkateswaramurthy Nallasamy. (2026). Cadasil And Carasil: A Mutated Hereditary Leukoencephalopathy – New Findings. World Journal of Pharmaceutical and Medical Research, 12(6), 55–62.

Article Received on 05/04/2026 **Article Revised on 25/04/2026** **Article Published on 01/05/2026**

INTRODUCTION

CADASIL - Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leuko- encephalopathy is a genetic disorder this is due to the mutation within the NOTCH3 gene.[1] NOTCH3 gene provides formation for producing the notch3 receptor proteins this is concerned within the functioning and survival of vascular smooth muscle groups. Mutation on this gene produces abnormal production of NOTCH3 receptor proteins that impairs the characteristic of the small blood vessels.[2] Clinical manifestations contain stroke, TIAs, migraine with aura, hypo densities of the white matter within the subcortical region, incidence of seizure and psychiatric disturbances and cognitive disturbances. There isn't any particular remedy for this situation it couldonly be treated symptomatically.[3] CADASIL is responsible for recurrent ischemic stroke during mid-adulthood and can lead to severe motor disability and cognitive decline.[4-5]

CARASIL – Cerebral Autosomal Recessive Arteriopathy with subcortical infarcts and leukoencephalopathy is a genetic disorder this is due of the mutation of the HTRA1 gene.[6] genetic archetype of nonhypertensive ischemic cerebral SVD and the most common heritable cause of stroke and vascular dementia in adults.[7]

This gene is involved in the production of proteins that are necessary for the functioning of organs and tissues.[8] The symptoms include increase in muscle rigidity, loss of bladder control, impaired speech and swallowing, alopecia, spondylitis.[9] The epidemiology of CADASIL is approximately 2 – 5 of 1,00,000 people. It affects both male and female in equal numbers.[10] On the other hand CARASIL gives off an impression of being an uncommon condition. It has been recognized in around 50 individuals, basically in Japan and China.[11] Till now there is no specific therapeutic treatment for CADASIL the only existing management is the symptomatic treatments such as anti-hypertensives, anti-convulsants, tPA therapy, acetaminophen and NSAIDs, anti-psychotics. As a consequence, novel therapeutic techniques, together with immunotherapy, increase elements administration, and antisense oligonucleotides, are presently below investigation. While waiting that in addition studies verify the promising outcomes acquired, the records reviewed advise that our healing technique to the ailment can be transformed, producing new wish for the better treatment approaches.[12]

This review article aims on establishing the ultra-modern findings within the higher therapeutic processes for SVDs such as CADASIL and CARASIL for better understanding of the condition and for drawing close popular approaches for diagnosis to keep away from misinterpretation as there are numerous comparable conditions that have an effect on the small blood vessels that supply blood to the subcortical location and causes hypo-densities in white matter including Fabry disease, Multiple sclerosis, MELAS, SVD and for identifying appropriatetreatment approaches in future.

NOTCH3 GENE

Notch3 is a huge type I transmembrane receptor, specifically expressed in vascular smooth muscle cells and pericytes close to the nearby blood vessels.[13] The NOTCH3 gene gives commands for making a protein with one end (the intracellular end) that stays inside the cell, a middle (transmembrane) segment that spans the cell membrane, and the other end (the extracellular end) that

initiates from the outer surface of the cell.[14] In human beings and mice, 4 Notch receptors(Notch1-4) have been recognized. All four Notch receptors are similar of their shape. As transmembrane receptors, they include an extracellular (NECD), and an intracellular domain (NICD). The NECD is expressed at the cell's surface after trans-Golgi preprocessing. It has an N- terminus inclusive of epidermal boom issue (EGF)-like repeats. The number of EGF-like repeats differs between Notch receptors.[15]

The human genome expresses four Notch receptors (NOTCH1-NOTCH4), and five ligands [(Delta-like 1) DLL1, DLL3 and DLL4, and Jagged1 (JAG1) and 2 (JAG2)]. All of these NOTCHreceptors are present inside the vasculature. NOTCH 2 and 3 are fairly expressed in vascular smooth muscle cells (VSMC), whilst NOTCH 1 and 4 are enormously expressed in endothelial cells (EC).[16] The $NOTCH3^{ECD}$ consists of 34 EGFr domains. These are modular protein subunits of about 40 amino acids, each containing a fixed variety of 6 cysteine residues. In pairs, those cysteines form three disulfide bridges, which can be crucial for EGFr secondary shape. NOTCH3mutations in CADASIL continuously lead to an uneven quantity of cysteines (generally 5 or 7) in the mutated EGFr. This effects in an unpaired cysteine, that is anticipated to disrupt normal disulfide bridge formation, inflicting miss-folding of EGFr and multiplied NOTCH 3 multi merization.

In patients, $NOTCH3^{ECD}$ is visible to build up in the vessel wall, in close proximity to VSMC. This $NOTCH3^{ECD}$ accumulation has a direct or indirect toxic impact on VSMC, leading to VSMC degeneration. Next to $NOTCH3^{ECD}$ accumulation and the presence of GOM, affected arteries display a thickened vessel wall with lumen stenosis, abundance of extracellular matrix proteins and destruction of VSMC. The vessel wall changes result in an impaired cerebrovascular reactivity and reduced cerebral blood with the flow, believed to purpose each continual cerebral ischemia and acute ischemic events.[17]

Notch3 in most cases serves a function in promoting most cancers improvement and it has been detected in more than one types of tumor, consisting of ovarian, cervical, breast and colon cancer. Compared with the results of Notch 3 WT, CADASIL mutants promoted the proliferation and migration of HeLa cells and inhibit these of breast most cancers cells.[18]

The first example of Notch3-related disease was reported in 1993, when mutations in the extracellular domain were identified in patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).[19]

THE ROLE OF NOTCH3 IN CANCER

The Notch family is a conserved gene group that regulates cell-cell interplay, embryogenesis, and tissue commitment. Notch signaling performs an essential function in cell fate determination and organogenesis. Notch signaling is an evolutionarily conserved signaling pathway that plays an important role in regulating, differentiation, proliferation, and apoptosis.[20-21]

Notch3 expression was found to be positively correlated with the Gleason score, and high expression of Notch3 was seen in prostate cancers with high metastatic potential. In breast most cancers cellular traces, Notch3 signaling turned into constitutively lively, and among different Notch receptors its activity was completely enough for selling tumor growth each in vitro and in vivo. Notch3 notably suppressed proliferation and promoted apoptosis of the ErbB2-poor tumor cell lines.

The role of Notch3 in epidermal-to-mesenchymal transition (EMT) of breast cancers is also controversial. While some investigators mentioned that Notch3 promotes tumor aggressiveness by means of inducing EMT, other investigators proven that Notch3 without a doubt opposes it.[22]

HTRA1 GENE

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is characterized by means of non-hypertensive cerebral small- vessel arteriopathy with subcortical infarcts, alopecia, and spondylosis, with an onset in early maturity. On neuropathological examination, arteriosclerosis related to intimal thickening and dense collagen fibers, lack of vascular smooth-muscle cells, and hyaline degeneration of the tunica media has been located in cerebral small arteries.[23] The presence of elevated ranges of several HTRA1 substrates in the CADASIL proteome become well matched with their reduced degradation as effect of a lack of HTRA1 interest.[24] A recessive inherited ailment, for a few HTRA1 mutations, the parents of the pro-bands with CARASIL present mild to severe white count lesions.[25] A excessive prevalence of HTRA1 mutations became currently said among sufferers with SVD, even though they lacked signs usual of CARASIL.[26]

HTRA1 ACTIVITY BY MUTANT HTRA1s:

HTRA1 exists as a trimer and is activated by using substrate-brought on cascade transmission to an adjacent HTRA1 subunit. 2 mutations determined in CARASIL, was higher than that of the manipulate combination; in assessment, the protease sports of all the other HTRA1 mixtures had been decrease than that of the manage aggregate, indicating that these HTRA1 mutants inhibit the protease hobby of untamed-type HTRA1.[25] As a end result of those mutations,the HTRA1 protein is misfolded and such heterozygous mutations in HTRA1 have a dominant bad impact, resulting in a big decrease in HTRA1-established protease hobby. The scientific features of those heterozygotes with HTRA1 had been a vulnerable phenotype of CARASIL, which includes

older age of onset of stroke and cognitive dysfunction, lower frequency of alopecia, and less intense white remember hyperintensites on mind MRI.[26]

The disorder progresses slowly following the onset of neurologic symptoms. Scalp alopecia and acute mid- to decrease-back ache (lumbago) earlier than age 30 years are feature. The most frequent preliminary symptom in people with HTRA1-CSVD is slowly progressive gait disturbance after age 40 years, which may be followed with the aid of the improvement of mood changes and cognitive disorder.[27-28]

The presence of increased levels of several HTRA1 substrates in the CADASIL proteome was compatible with their reduced degradation as consequence of a loss of HTRA1 activity.[24]

PATHOLOGY IN CARASIL

In 1976, Maeda et al reported familial unusual encephalopathy of the Binswanger's type without hypertension in siblings whose parents were consanguineous. In 2009, Hara et al diagnosed that the mutation inside the excessive-temperature requirement serine peptidase A1 (HTRA1) gene codes a protease in sufferers with CARASIL. In the cerebral small arteries, smooth muscle cells were substantially misplaced, even in arteries without sclerotic changes. Sclerotic changes had been slight and rare; most of the arteries were enlarged in place of displaying luminal stenosis. Tunica media of the cerebral small arteries exhibited hyalinosis and were immunopositive for fibrinogen. These pathological findings resemble the ones discovered in nonhereditary ischemic CSVD. In the sufferers with non-hereditary ischemic CSVD, marked degeneration of vascular easy muscle cells with crumble and dilatation inside the cerebral small arteries, the so- referred to as earthen pipe phenomenon, have been found. These modifications may disturb autoregulatory mechanisms for cerebral blood glide, resulting in ischemic modifications within the deep white remember.[29]

CLINICAL MANIFESTATIONS AND REPORTS

The deep WM and periventricular space, wherein aberrant axons and more than 1 small infarcts with gliosis had been discovered, while the temporal WM turned into noticeably properly preserved. Similarly, it is found that arteriolosclerosis changed into accentuated inside the periventricular area of the frontal CSO and basal ganglia, followed through capillary exchange related to lack of endothelial cells with wall thickening in both the hereditary and sporadic SVD corporations, even though function vascular changes in CADASIL and HTRA1-AD together with deposition of basophilic granules with tremendous immune reactivity for $NOTCH3^{ECD}$ inside the SMC or multi-layering of the inner elastic lamina, extended for the duration of the mind.[30]

Migraine with aura is the most common providing complaint. It is typically associated with visual and sensory symptoms. However, in a few patients, motor and brainstem signs and symptoms also are present migraine can also occur without aura. Other manifestation consists of weak point or paralysis of the face, arm, leg, foot, sudden numbness; difficulty taking walks; issue talking; clumsiness of a hand or arm; weakness or paralysis of ocular muscle; cognitive decline typically associated with executive characteristic; verbal/visual reminiscence, reasoning, and language deficit; seizures; and emotional disturbances like apathy. Although rare, some sufferers document spinal signs and symptoms, depending on the type of vasculature involved. A comparable situation known as cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) has a comparable presentation. However, the vital distinction is the absence of migraine with aura with cognitive decline taking place before other symptoms.[31] Vascular lesions in CARASIL and HTRA1-associated CSVD may additionally arise due to a fault in the transforming increase component (TGF-β) signaling pathway. The TGF-β binding protein, observed inside the extracellular matrix, is one of the HTRA1 proteolyticsubstrates.

The decreased HTRA1 proteolytic pastime because of pathogenic variants within the gene dysregulates the TGF-β signaling inhibition and leads to vasculopathy.[32] The vasodilator responses of both cerebral and extra cerebral arterioles were greater seriously impaired in symptomatic sufferers with SVD had been matched for primary vascular comorbidities substantially decrease inside the subgroup of patients with sizeable radiologic markers of SVD: particularly, extreme white matter lesions, enlarged perivascular spaces, and intense brain atrophy.[33]

WMH are speculated to be complete expressions consisting of disturbances of small blood vessels, breakdown of the BBB, small infarcts within the white matter, glial activation, lack of oligodendrocytes, and demyelination due to persistent diffuse hypo-perfusion or decreased cerebral blood flow.[34] Perivascular spaces as seen on MRI are associated with numerous small vessel ailment-associated factors—hypertension, circulating inflammatory markers, and cognitive decline that (like numerous other small vessel disease lesions) are particularly heritable.

Furthermore, perivascular space visibility improved with increasing white mater hyper intensities, micro bleeds, and cerebral amyloid-angiopathy and in lacunar as opposed to non- lacunar stroke, mediated the might association between plasma inflammatory markers and white remember hyper-intensities, predict progression of white of the BBB, small infarcts within the white matter, glial activation, lack of oligodendrocytes, and demyelination due to persistent diffuse hypo-perfusion or decreased cerebral blood flow.[35]

Pre-stroke TIA, ischemic heart sickness, peripheral arterial disease, and atrial traumatic inflammation have been all much less not unusual in participants with lacunar stroke than in those with non-lacunar strokes, assisting previous research demonstrating that massive artery disorder and cardio-embolic resources are essential threat factors for non-lacunar, however much less so for lacunar ischemic strokes.[36] Other possible pathologies include antique hematomas, intact erythrocytes and, very not often, vascular pseudo-calcification, micro-aneurysm and distended dissected vessels. Lippo-fibro-hyalinosis and amyloid angiopathy are the maximum common vascular findings. In fashionable, disrupted BBB would permit plasma fluid components and blood cells to enter the vessel wall, leading to disintegration of the vessel wall and fibrin deposition.

If this takes place at arterioles where there's smooth muscle, the additives deposited inside the arteriolar wall could result in dilation and narrowing of the vessel lumen and vessel wall thickening, which could eventually precipitate inflammation, platelet adhesion, luminal occlusion and accordingly traditional infarct.[37] Delirium is related to worse WMH severity, suggesting that individuals with underlying small vessel disorder have extra frail brains, wherein regions of vascular dysfunction can be extra prone to acute impairment following systemic inflammatory insults.[38]

CLINICAL FEATURES OF HETEROZYGOTES WITH HTRA1 MUTATION

Threat factors for stroke, including hypertension, a history of heavy alcohol intake, or a history of smoking. The clinical hallmarks of CARASIL, Spondylosis deformans became detectedin all cases. Alopecia became detected in three patients inside the frontal area, as observed in CARASIL. Brain MRI revealed hyper-intensities in deep white rely with lacunar infarcts and micro-bleeds white count number lesions in the anterior temporal lobe were milder than the ones in CARASIL. Brain atrophy offered predominantly in the vital place and the frontal lobe. Spinal MRI confirmed diffuse spondylosis deformans at the cervical backbone. Single photon emission CT showed hypo-perfusion inside the frontal and temporal lobes, thalamus, and brainstem. The cerebral small arteries confirmed intimal proliferation, hyaline degeneration of media, and splitting of the internal elastic lamina.[25-37] Alopecia, spondylosis, and cognitive impairment are the scientific triad. Alopecia does not necessarily appear in all sufferers with CARASIL, however this option contributes to an early diagnosis.[37]

Reduction of type IV collagen immunoreactivity was observed in both CARASIL and CADASIL patients. This suggests that basement membrane-related type IV collagen is non- specifically decreased due to the medial SMC loss. On the other hand, immunoreactivities of type I, III and VI collagens and fibronectin were specifically decreased in CARASIL.[38]

NEUROLOGICAL INVESTIGATION

To prioritize access to genetic checking out for suspected CADASIL patients, a quantitative evaluation of CADASIL-precise features possessed by using each affected person is necessary. Mark us proposed a diagnostic technique primarily based on pores and skin biopsy and involvement of the anterior temporal lobe on MRI (Markus et al., 2002).[39] Jouvent et al. (2011b) used high-decision postmortem 7-T MRI to observe infarcts of the cerebral cortex in a CADASIL affected person with pathology examination.[40]

The CADASIL prognosis can handiest be showed by way of DNA test of blood samples for function mutations inside the NOTCH3 gene or through figuring out granular osmiophilic material (GOM) inclusions on a skin biopsy.[41] Imaging modalities which include flu-deoxy glucose positron emission tomography (FDG-PET) and diffusion tensor imaging (DTI) have been used to look at cerebral functional changes associated with CADASIL.,[42] higher degrees of CSF and/or blood protein are expected to predict a faster ailment progression, higher grade of useful impairment, and/or shorter survival, which are all relevant variables for the stratification and control of sufferers in ongoing clinical trials.[43] TEM and NTA have been implemented on the way to degree the morphology and length distribution of plasma exosomes. It has indicated that exosomes can also shrink or trade size throughout coaching for TEM, but TEM remains useful for watching the morphology and structure of exosomes. The exosome distribution in healthy subjects is notably scattered and uniform, and exosome diameter is noticeably smaller.[44]

NEW FINDINGS

Novel R558C mutation-related CADASIL vasculopathy and several CMBs, un-controlled high blood pressure, and antiplatelet therapy might also need to collectively contribute to ICH onset in the affected person with CADASIL. These findings recommend that the analysis of CADASIL have to be taken into consideration even as patients present with ICH, whenever MRI imaging reveals normal white matter abnormalities.[45] The associations among fibrinogen and WMHs were now not enormous in CSVD sufferers after the adjustment for age. The discrepancy between CADASIL and CSVD patients can be defined by means of the fibrinogen tiers increasing with age in CSVD however now not in CADASIL sufferers. The precise mechanism with the aid of which elevated fibrinogen would possibly make contributions to WMHs stays unknown.

However, WMHs are considered to reflect ischemic small vessel disease. Fibrinogen triggers diverse atherogenic techniques which include endothelial injures. Thus, fibrinogen might sell atherogenesis in small vessels. Elevated fibrinogen ranges set off hypercoagulability and can replicate the development of

atherosclerosis. Such hem rheological impairments because of increased tiers of fibrinogen would aggravate cerebral hypo perfusion. Hyper-fibrinogenemia could be alleviated via making way of life modifications or drug utilization.[46]

RS-fMRI in CADASIL sufferers found out a reduced regional homogenecity of the BOLD register cortical areas which might be worried within the inhibition and attention strategies, alongside the right insular cortex, the left advanced frontal gyrus, and the bilateral anterior cingulated gyrus. These sensible modifications did now not correlate with the extension and severity of the WM harm assessed through T2-weighted FLAIR imaging and DTI, respectively. To date, one observe has evaluated sufferers with sporadic early SVD, and two studies have evaluated CADASIL patients using RS-fMRI.[47] We recognized a subgroup of male patients whose mind volume and clinical consequences were just like the ones of age-matched women. They did no longer have a selected distribution of the epidermal growth aspect repeat area, suggesting that yet-unidentified predictors may additionally engage with intercourse and brain extent in driving disease evolution.[48]

A comparable mechanism has been proposed within the pathogenesis of COVID-19- associated posterior reversible encephalopathy syndrome (PRES), another neurological condition in which endothelial disorder and coagulopathy, together with a cytokine storm because of the contamination, may additionally lead to pathological modifications.

Accordingly, in sufferers with genetic conditions characterized by means of stroke recurrence, inclusive of CADASIL, we must be aware about an excellent better danger of ischemicstroke within the case of SARS-CoV-2 infection. Careful evaluation and active monitoring of these prone patients within the time of pandemics is consequently obligatory.[49]

Vascular $NOTCH3^{ECD}$ aggregation load is decrease in CADASIL sufferers with a $NOTCH3^{cys}$ EGFr 7–34 variant than in patients with a $NOTCH3^{cys}$ EGFr 1–6 variation. This locating suggests that there is a difference in aggregation properties between EGFr 1–6 and EGFr7–34 $NOTCH3^{cys}$ mutant proteins. A decrease vascular $NOTCH3^{ECD}$ aggregation load can be oneof the elements underlying the later and milder ailment onset in CADASIL sufferers with an EGFr 7–34 variation in comparison to patients with an EGFr 1–6 variant.[50]

There are kinds of CADASIL-related mutations. One is a sign-active (SA) mutation that happens outside the ligand-binding area of NOTCH3. The SA NOTCH3 mutant keeps the potential to bind to a ligand and transduce NOTCH indicators. The different is a sign-deficient (SD) mutation in the ligand-binding domain of NOTCH3, which compromises NOTCH3 feature.[51] Based on our already established results (via exhaustive molecular dynamics simulations) it changed into located that non-Cys mutations trigger huge lack of structure in the Notch3 protein, in comparison to the wild kind. Currently, there's no healing remedy to be had for CADASIL andthere is of drug which can act in particular at the Notch3 protein receptor.

Medical practitioners prescribe aspirin, dipyridamole, or clopidogrel, or a combination of these, which might be discovered to restriction the signs and symptoms of the disorder and to exceedingly slow it down. Given that all conventional tries have failed in figuring out an ailment-editing remedy, an intensive in silico analysis of the Notch3 mutations and of the ensuing angiogenic plasticity of the CADASIL phenotype on small vessels, may need to be doubtlessly cause a thorough early detection pipeline.

The latter coupled by way of recent breakthroughs in OCT-A generation, photo evaluation and computational biology are steadily gaining floor in neurodegenerative disorder treatments under the emerging prism of preventive and precision remedy.[52] Medical functions and CT and MRI changes are regular with acute subcortical multiple infarctions which can be related to or provoked by a viral infection. Further genetic trying out revealed this previously asymptomatic patient to have a pathogenic variant of the NOTCH3 gene consistent with CADASIL. Even although its miles regarded that there are vascular wall smooth muscle abnormalities associated with CADASIL gene mutations, it isn't always clean what triggers the multiple infarcts in these patients. Acute Contamination likely triggered a milieu of inflammation, hypoxia, and coagulopathy on this COVID-19 patient which prompted multiple infarcts. Further research as to the precipitants of the hypoxic–ischemic procedure in CADASIL patients is of interest.

It is plausible that small vessel ailment affecting the striatonigral or the thalamo-cortical pathways is in most cases responsible for parkinsonian phenotype in CADASIL patients, leading to a disconnection inside the motor circuit.[53]

CADASIL IN PREGNANCY

She becomes identified with CADASIL at the age of 26. She has been affected by migraine; her assaults had been characterized by way of a throbbing and stabbing ache in the temporal area associated to photo/phono phobia and nausea. Because the worst episodes lasted greater than five days without responding to any analgesics, she changed to place on acetazolamide as migraine prophylaxis with a progressive accurate manipulation of assaults. She had pregnancies, the first at the age of 26, and the second one at 30. Both have been without gestational complications. At 36 weeks of her first being pregnant, she underwent emergency cesarean shipping for fetal breech presentation; the second being pregnant resulted in a vaginal birth at the period (at 37 weeks+ days). The newborn weights had been in the 71st and

74th percentile, respectively. During both pregnancies, she stopped acetazolamide due to the danger of electrolyte imbalance and her migraine worsened. No other drug was changed into prescribed.

The majority of sufferers with CADASIL have a family history of absence of vascular disease consequences factors which include high blood pressure, diabetes, coronary heart disorder, and smoking.[54]

CONCLUSION

This review article aims on summarizing the new findings in the rare hereditary cerebral diseases CADASIL and CARASIL. This rare disease can only be treated symptomatically and is caused by the mutation of specific genes which are NOTCH 3 and HTRA 1 gene. There are lots of studies and researches going on about this disease. Here we have summarized the possible findings so far about this disease and about this condition in pregnancy. This is a vast field and involves several types of mutations to consider. We have attempted to concise the information. The drug treatment depends only upon the symptoms and during pregnancy it is reported that if the drugs are withdrawn for the safety of the fetus the symptoms are increased and it is difficult for the patient to manage. There are numerous methods which are used for the diagnosis of this condition which involves blood DNA analysis and specific MRI tests and can be diagnosed easily. A lot of researches should be carried on the treatment considerations of this condition. This might be challenging for the scientists and physicians as this is a rare genetic disease.

REFERENCES

1. Hedera P. NOTCHing toward better understanding of CADASIL. *Neurology.* 2020; 95(13): 565-566.
2. Sung PS, Pai MC. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *Acta Neurologica Taiwan*., 2008; 17(4): 295-296.
3. Wang MM. CADASIL. In: Neurogenetics, Part II. Elsevier, 2018: 733-743.
4. Guey S, Mawet J, Hervé D, et al. Prevalence and characteristics of migraine in CADASIL. *Cephalalgia*. 2016; 36(11): 1038-1047. doi:10.1177/0333102415620909.
5. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. *American Neurological Assocition*., 1998; 44(5): 731-739. doi:10.1002/ana.410440506.
6. Uemura M, Nozaki H, Onodera O. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). *Brain Nerve*., 2017; 69(1): 25- 33.
7. Hara K, Shiga A, Fukutake T, *et al*. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. *New England Journal of Medicine,* 2009; 360(17): 1729-1739. doi:10.1056/NEJMoa0801560
8. HTRA1 gene. Medlineplus.gov. Accessed on October 10, 2022. Available at https://medlineplus.gov/genetics/gene/htra1/.
9. Thu PW, Lo RY. A study of seven patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in eastern Taiwan: A case series with literature review. *Acta Neurology Taiwan*, 2021; 30(4): 162-170.
10. CADASIL - NORD (national organization for Rare disorders). NORD (National Organization for Rare Disorders). Published on February 11, 2015. Accessed on October 10, 2022. Available at https://rarediseases.org/rare-diseases/cadasil/.
11. Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. In: Magnetic Resonance of Myelination and Myelin Disorders. Springer Berlin Heidelberg, 2005; 549-551.
12. Manini A, Pantoni L. CADASIL from bench to bedside: Disease models and novel therapeutic approaches. *Molecular Neurobiology*, 2021; 58(6): 2558-2573.
13. Papakonstantinou E, Bacopoulou F, Brouzas D, et al. NOTCH3 and CADASIL syndrome: a genetic and structural overview. *EMBnet Journal*., 2019; 24: e921.
14. NOTCH3 gene. Medlineplus.gov. Accessed on October 10, 2022. Available at https://medlineplus.gov/genetics/gene/notch3/.
15. Ballhause TM, Jiang S, Baranowsky A, *et al*. Relevance of Notch signaling for bone metabolism and regeneration. *International Journal of Molecular Science*, 2021; 22(3): 1325.
16. Oliveira DV. Unraveling the Role of NOTCH3 Dysfunction in Disease and for Therapy Development: A Focus on Cadasil. 2021.
17. Rutten JW, Haan J, Terwindt GM, van Duinen SG, Boon EMJ, Lesnik Oberstein SAJ. Interpretation of NOTCH3mutations in the diagnosis of CADASIL. Expert Review of Molecular Diagnosis, 2014; 14(5): 593-603.
18. Lin C, Huang Z, Zhou R, *et al*. Notch3 and its CADASIL mutants differentially regulate cellular phenotypes. *Experimental and Therapeutic Medicine*, 2021; 21(2): 117.
19. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult- onset condition causing stroke and dementia. *Nature*, 1996; 383(6602): 707-710. doi:10.1038/383707a0
20. Aburjania Z, Jang S, Whitt J, Jaskula-Stzul R, Chen H, Rose JB. The Role of *Notch3* in Cancer. *Oncologist*., 2018; 23(8): 900-911. doi:10.1634/theoncologist.2017-0677
21. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. *Medical Oncology*, 2010; 27(3): 1017-1022. doi:10.1007/s12032-009-9326-5
22. Hara K, Shiga A, Fukutake T, *et al*. Association of HTRA1 mutations and familial ischemic cerebral

small-vessel disease. *New England Journal of Medicine*, 2009; 360(17): 1729-1739. doi:10.1056/NEJMoa0801560.
23. Zellner A, Scharrer E, Arzberger T, *et al*. CADASIL brain vessels show a HTRA1 loss-of- function profile. *Acta Neuropathologica*, 2018; 136(1): 111-125. doi:10.1007/s00401-018-1853-8.
24. Nozaki H, Kato T, Nihonmatsu M, *et al*. Distinct molecular mechanisms of HTRA1 mutants in manifesting heterozygotes with CARASIL. *Neurology*, 2016; 86(21): 1964-1974. doi:10.1212/WNL.0000000000002694.
25. Kono Y, Nishioka K, Li Y, *et al.* Heterozygous HTRA1 mutations with mimicking symptoms of CARASIL in two families. *Clinical Neurology and Neurosurgery*, 2018; 172: 174-176. doi:10.1016/j.clineuro.2018.07.009.
26. Onodera O, Nozaki H, Fukutake T. HTRA1 Disorder. Published on April 27, 2010. Updated on November 7, 2019. Accessed on August 12, 2022 In: Adam MP, Everman DB, Mirzaa GM, *et al.*, Available at https://www.ncbi.nlm.nih.gov/books/NBK32533/.
27. Nozaki H, Nishizawa M, Onodera O. Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. *Stroke*, 2014; 45(11): 3447-3453. doi:10.1161/STROKEAHA.114.00423
28. Saito R, Tainaka K, Nozaki H, *et al*. Small vessel diseases: 3D characteristics of the vasculature and white matter. bioRxiv. Published online 2021.
29. Ameer MA, Bhutta BS, Asghar N, Haseeb MT, Abbasi RN. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) presenting as migraine. Cureus. Published online 2021.
30. Grigaite J, Siauryte K, Audronyte E, *et al*. Novel in-frame deletion in HTRA1 gene, responsible for stroke at a young age and dementia-A case study. *Genes (Basel).*, 2021; 12(12): 1955.
31. Staszewski J, Skrobowska E, Piusinska-Macoch R, Brodacki B, Stępien A. Cerebral and extracerebral vasoreactivity in patients with different clinical manifestations of cerebral small-vessel disease: Data from the significance of hemodynamic and hemostatic factors in the course of different manifestations of cerebral small-vessel disease study. *Journal of Ultrasound Medication*, 2019; 38(4): 975-987.
32. Li Q, Yang Y, Reis C, *et al.* Cerebral small vessel disease. *Cell Transplant*, 2018; 27(12): 1711-1722.
33. Appleton JP, Woodhouse LJ, Adami A, *et al*. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. *Neurology*, 2020; 94(5): e439-e452.
34. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. *Stroke and Vascular Neurology*, 2016; 1(3): 83-92.
35. Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal FN, Wardlaw JM. Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis. *Lancet Psychiatry*, 2021; 8(3): 225-236.
36. Chabriat H, Bousser MG. Neuropsychiatric manifestations in CADASIL. *Dialogues in Clinical Neuroscience*, 2007; 9(2): 199-208.
37. Nishimoto Y, Shibata M, Nihonmatsu M, et al. A novel mutation in the HTRA1 gene causes CARASIL without alopecia. *Neurology*, 2011; 76(15): 1353-1355. doi:10.1212/WNL.0b013e318215281d
38. Oide T, Nakayama H, Yanagawa S, Ito N, Ikeda S, Arima K. Extensive loss of arterial medial smooth muscle cells and mural extracellular matrix in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). *Neuropathology*, 2008; 28(2): 132-142. doi:10.1111/j.1440- 1789.2007.00864.x
39. Mizuno T, Mizuta I, Watanabe-Hosomi A, Mukai M, Koizumi T. Clinical and Genetic Aspects of CADASIL. *Frontiers Aging Neuroscience*, 2020; 12: 91.
40. CADASIL - NORD (national organization for Rare disorders). NORD (National Organization for Rare Disorders). Published on February 11, 2015. Accessed on October 10, 2022. Available at https://rarediseases.org/rare-diseases/cadasil/.
41. Zhu S, Nahas SJ. CADASIL: Imaging Characteristics and Clinical Correlation. *Current Pain Headache Reports*, 2016; 20(10): 57.
42. Abu-Rumeileh S, Parchi P. Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art. *Frontier Neuroscience*, 2021; 15: 648743.
43. Gao D, Shang J, Sun R, *et al.* Changes in the Morphology, Number, and Protein Levels of Plasma Exosomes in CADASIL Patients. *Journal of Alzheimers Disease*, 2021; 81(1): 221-229.
44. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. *International Journal of Stroke*, 2018; 13(6): 612-632.
45. Guo X, Deng B, Zhong L, *et al*. Fibrinogen is an Independent Risk Factor for White Matter

Hyperintensities in CADASIL but not in Sporadic Cerebral Small Vessel Disease Patients. *Aging and Disease*, 2021; 12(3): 801-811.
46. Orsolini S, Marzi C, Gavazzi G, *et al.* Altered Regional Brain Homogeneity of BOLD Signal in CADASIL: A Resting State fMRI Study. *Journal of Neuroimaging*, 2021; 31(2): 348-355.
47. Lebenberg J, Guichard JP, Guillonnet A, *et al*. The Epidermal Growth Factor Domain of the Mutation Does Not Appear to Influence Disease Progression in CADASIL When Brain Volume and Sex Are Taken into Account. *AJNR American Journal of Neuroradiol*ogy, 2022; 43(5): 715-720.
48. Cruciani A, Pilato F, Rossi M, Motolese F, Di Lazzaro V, Capone F. Ischemic Stroke in a Patient with Stable CADASIL during COVID-19: A Case Report. *Brain Science*, 2021; 11(12): 1615. doi: 10.3390/brainsci11121615
49. Gravesteijn G, Hack RJ, Mulder AA, *et al*. NOTCH3 variant position is associated with NOTCH3 aggregation load in CADASIL vasculature. *Neuropathology and Applied Neurobiology*, 2022; 48(1): e12751. doi: 10.1111/nan.12751
50. Suzuki S, Hiura S, Mashiko T, Matsumoto T, Itoh M. Lunatic fringe promotes the aggregation of CADASIL NOTCH3 mutant proteins. *Biochemical and Biophysical Research Communication*, 2021; 557: 302-308. doi: 10.1016/j.bbrc.2021.04.031.
51. Papakonstantinou E, Bacopoulou F, Brouzas D, *et al*. NOTCH3 and CADASIL syndrome: a genetic and structural overview. *EMBnet Journal*, 2019; 24: e921. doi:10.14806/ej.24.0.921
52. Zhang T, Hirsh E, Zandieh S, Rodricks MB. COVID-19-Associated Acute Multi-infarct Encephalopathy in an Asymptomatic CADASIL Patient. *Neurocritical Care*, 2021; 34(3): 1099-1102.
53. Spagnolo F, Pinto V, Rini AM, Passarella B. Dystonia and parkinsonism as presenting CADASIL features: a case report. *Neurological Sciences*, 2021; 42(11): 4781-4783.
54. Donnini I, Rinnoci V, Nannucci S, *et al.* Pregnancy in CADASIL. *Acta Neurologica Scand*inavica, 2017; 136(6): 668-671.